IgD型多发性骨髓瘤的诊治现状及展望

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R] 期数: 2019年14期 页码: 2604-2607 栏目: 综述 出版日期: 2019-06-08

Title: Current status and prospect of diagnosis and treatment of IgD multiple myeloma

作者: 宋变变; 廖爱军
中国医科大学附属盛京医院血液内科，辽宁 沈阳 110004

Author(s): Song Bianbian; Liao Aijun
Department of Hematology,Shengjing Hospital of China Medical University，Liaoning Shenyang 110004,China.

关键词: IgD型多发性骨髓瘤; 诊断; 治疗

Keywords: IgD multiple myeloma; diagnosis; treatment

分类号: R733.3

DOI: 10.3969/j.issn.1672-4992.2019.14.042

文献标识码: A

摘要: IgD型多发性骨髓瘤（IgD multiple myeloma，IgD MM）是多发性骨髓瘤（multiple myeloma，MM）中一种罕见类型，以年轻男性患者居多。主要表现为高钙血症、肾衰竭、贫血、骨损害、髓外浸润和系统性淀粉样变性等，具有侵袭性高，预后较差的特点。近年来，随着免疫调节剂（沙利度胺、来那度胺）、蛋白酶抑制剂（硼替佐米）等药物以及自体造血干细胞移植（autologous stem cell transplantation，ASCT）的应用，IgD型MM的预后得到明显改善。新一代蛋白酶体抑制剂、CD38单克隆抗体、组蛋白去乙酰化酶抑制剂（histone deacetylase inhibitor,HDACI）、新型免疫治疗技术等治疗方法也为IgD型MM 的治疗提供了新的方向。目前关于IgD型MM的相关报道较少，本文就IgD型MM的临床特点、诊断、治疗、预后及新药研究现状进行如下综述。

Abstract: IgD multiple myeloma (IgD MM) is a rare type of multiple myeloma (MM),and the majority of patients are young men.It is characterized as hypercalcemia,renal insufficiency,anemia,bone disease,extramedullary infiltration and amyloidosis.Besides,IgD MM is invasive and has poor prognosis.In recent years,the prognosis of IgD MM has been significantly improved with the application of immunomodulators (thalidomide,lenalidomide),proteasome inhibitors (bortezomib) and other drugs,as well as autologous stem cell transplantation (ASCT).The new generation of proteasome inhibitors,CD38 monoclonal antibodies,histone deacetylase inhibitor (HDACI) and new immunotherapy technologies also provide new directions for the treatment of IgD MM.Due to the few reports on the disease of IgD MM,this article is going to review the IgD MM on clinical characteristics,diagnosis,treatment,prognosis and research status of new drugs.

参考文献/REFERENCES

[1] Bladé J,Kyle RA.Nonsecretory myeloma,immunoglobulin D myeloma,and plasma cell leukemia [J] .Hematol Oncol Clin North Am,1999,13(6):1259-1272.
[2] Kyle RA,Rajkumar SV.Multiple myeloma [J] .N Engl J Med,2004,351(18):1860-1873.
[3] Reisenbuckler C.Mutiple myeloma and diagnostic imaging [J] .Radio Techno,2014,85(4):391-410.
[4] Siegel R,Naishadham D,Jemal A.Cancer statistics for Hispanics/Latinos [J] .CA Cancer J Clin,2012,62(5):283-298.
[5] Kyle RA,Gertz MA,Witzig TE,et al.Review of 1 027 patients with newly diagnosed multiple myeloma [J] .Mayo Clin Proc,2003,78(1):21-33.
[6] Chong YP,Kim S,Ko OB,et al.Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation:A single center experience [J] .J Korean Med Sci,2008,23(5):819-824.
[7] Kim MK,Suh C,Lee DH,et al.Immunoglobulin D multiple myeloma:Response to therapy,survival,and prognostic factors in 75 patients [J] .Ann Oncol,2011,22(2):411-416.
[8] Bladé J,Lust JA,Kyle RA.Immunoglobulin D multiple myeloma:Presenting features,response to therapy,and survival in a series of 53 cases [J] .J Clin Oncol,1994,12(11):2398-2404.
[9] Ma HX,Fan SY,Guo SL.The seroimmunological analysis of 117 multiple myeloma cases in Xinjiang [J] .Chin J Prim Med Pharm,2010,17(22):3073-3074.[马慧霞，范淑英，郭淑丽．多发性骨髓瘤117例血清免疫学特征分析 [J] ．中国基层医药，2010，17（22）：3073-3074．]
[10] Bladé J,Kyle RA,Greipp PR.Presenting features and prognosis in 72 patients with multiple myeloma who

were younger than 40 years [J] .Br J Haematol,1996,93(2):345-3451.
[11] Lu J,Lu J,Chen W,et al.Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma:Results of a multicenter analysis [J] .Blood Cancer J,2014,4:e239.
[12] Reece DE,Vesole DH,Shrestha S,et al.Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation:A retrospective CIBMTR study [J] .Clin Lymphoma Myeloma Leuk,2010,10(6):458-463.
[13] Kyle RA,Rajkumar SV.Criteria for diagnosis,staging,risk stratification and response assessment of multiple myeloma [J] .Leukemia,2009,23(1):3-9.
[14] Varettoni M,Corso A,Pica G,et al.Incidence,presenting features and outcome of extramedullary disease in multiple myeloma:A longitudinal study on 1 003 consecutive patients [J] .Ann Oncol,2010,21(2):325-330.
[15] Kyle RA,Maldonado JE,Bayrd ED.Plasma cell leukemia.Report on 17 cases [J] .Arch Intern Med,1974,133(5):813-818.
[16] Noel P,Kyle RA.Plasma cell leukemia:An evaluation of response to therapy [J] .Am J Med,1987,83(6):1062-1068.
[17] Epstein J,Xiao HQ,He XY.Markers of multiple hematopoietic-cell lineages in multiple myeloma [J] .N Engl J Med,1990,322(10):664-668.
[18] Arpin C,de Bouteiller O,Razanajaona D,et al.The normal counterpart of IgD myeloma cells in germinal center displays extensively mutated IgVH gene,Cmu-Cdelta switch,and lambda light chain expression [J] .J Exp Med,1998,187(8):1169-1178.
[19] Pandey S,Kyle RA.Unusual myelomas:A review of IgD and IgE variants [J] .Oncology (Williston Park),2013,27(8):798-803.
[20] Shimamoto Y.IgD myeloma:Clinical characteristics and a new staging system based on analysis of Japanese patients [J] .Cancer Detect Prev,1995,19(5):426-435.
[21] Shimamoto Y,Anami Y,Yamaguchi M.A new risk grouping for IgD myeloma based on analysis of 165 Japanese patients [J] .Eur J Haematol,1991,47(4):262-267.
[22] Morris C,Drake M,Apperley J,et al.Efficacy and outcome of autologous transplantation in rare myelomas [J] .Haematologica,2010,95(12):2126-2133.
[23] Wang GR,Sun WJ,Chen WM,et al.Immunoglobulin D multiple myeloma:Disease profile,therapeutic response,and survival [J] .Acta Haematol,2016,136(3):140-146.
[24] An R,He HY,Jiang H,et al.Clinical characteristics and prognosis analysis of 130 cases with IgD multiple myeloma [J] .J Clin Hematol,2017,30(3):194-197.[安然，何海燕，姜华，等．130例IgD型多发性骨髓瘤临床特点及预后分析［J］．临床血液血液性杂志，2017，30（3）：194-197．]
[25] Nair B,Waheed S,Szymonifka J,et al.Immunoglobulin isotypes in multiple myeloma:Laboratory correlates and prognostic implications in total therapy protocols [J] .Br J Haematol,2009,145(1):134-137.
[26] Fibbe WE,Jansen J.Prognostic factors in IgD myeloma:A study of 21 cases [J] .Scand J Haematol,1984,33(5):471-475.
[27] Jancelewicz Z,Takatsuki K,Sugai S,et al.IgD multiple myeloma.Review of 133 cases [J] .Arch Intern Med,1975,135(1):87-93.
[28] Dimopoulos MA,Terpos E.Advances in the treatment of multiple myeloma [J] .Eur J Cancer,2011,47 Suppl 3:S306-308.
[29] Dimopoulos MA,Palumbo A,Attal M,et al.Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma:Consensus statement [J] .Leukemia,2011,25(5):749-760.
[30] Kr□nke J,Udeshi ND,Narla A,et al.Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells [J] .Science,2014,343(6168):301-305.
[31] Gandhi AK,Kang J,Havens CG,et al.Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.) [J] .Br J Haematol,2014,164(6):811-821.
[32] Paramore A,Frantz S.Bortezomib [J] .Nat Rev,2003,2:611-612.
[33] Johnson TR,Stone K,Nikrad M,et al.The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells [J] .Oncogene,2003,22(32):4953-4963.
[34] Wechalekar A,Amato D,Chen C,et al.IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation [J] .Ann Hematol,2005,84(2):115-117.
[35] Maisnar V,Hájek R,Scudla V,et al.High-dose chemotherapy followed by autologous stem cell transplantation changes prognosis of IgD multiple myeloma [J] .Bone Marrow Transplant,2008,41(1):51-54.
[36] Attal M,Harousseau JL,Stoppa AM,et al.A prospective,randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J] .Intergroupe Francais du Myélome,N Engl J Med,1996,335(2):91-97.
[37] Barlogie B.High-dose therapy and innovative approaches to treatment of multiple myeloma [J] .Semin Hematol,2001,38(2 Suppl 3):21-27.
[38] Barlogie B,Tricot GJ,van Rhee F,et al.Long-term outcome results of the first tandem autotransplant trial for multiple myeloma [J] .Br J Haematol,2006,135(2):158-164.
[39] Sharma M,Qureshi SR,Champlin RE,et al.The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes [J] .Am J Hematol,2010,85(7):502-504.
[40] Kang J,Hong JY,Yoon DH,et al.Efficacy and survival outcome associated with the use of novel agents and autologous stem cell transplantation in cases of immunoglobulin D multiple myeloma in korea [J] .Acta Haematol,2018,139(3):185-192.

备注/Memo: National Natural Science Foundation of China(No.81272629）；国家自然科学基金（编号：81272629）；沈阳市科技计划项目（编号：17-231-1-58）

更新日期/Last Update: 1900-01-01